5 November 2025 in Science Translational Medicine
Plasmacytoid dendritic cells (pDCs) rapidly produce type I interferon (IFN-I) in response to acute virus infections. During chronic HIV-1 infection, persistent activation of pDCs contributes to inflammatory diseases. Combination antiretroviral therapy (cART) effectively suppresses HIV-1 replication and prolongs the life span of people living with HIV-1 (PLWH). The persistence of viral reservoir cells under cART, however, is associated with suboptimal immune reconstitution, impaired anti-HIV immunity, and non–AIDS-defining inflammatory diseases through unclear mechanisms. We report here that pDC depletion in HIV-infected humanized mice with suppressive cART alleviated HIV-associated inflammation, reversed T cell immune exhaustion, enhanced HIV-specific CD8 + T cell responses, and reduced HIV-1 reservoirs in lymphoid and nonlymphoid tissues through CD8 + T cell–dependent mechanisms. Specifically, pDC depletion in the mice led to an increase in TCF-1 + PD-1 + Tim-3 − stem-like memory CD8 + T cells in HIV-infected lymphoid tissues, which correlated with a reduction in the HIV-1 reservoir. We further showed that pDCs suppressed the polyfunctional activity of anti-HIV stem-like memory CD8 + T cells isolated from PLWH in vitro. As in the HIV-infected humanized mice, pDC depletion or IFN-I blockade functionally rescued the stem-like memory CD8 + T cells, enhancing their anti-HIV responses. Combination therapy with PD-1 blockade further improved stem-like memory T cell function both in vitro and in HIV-infected humanized mice. Our findings indicate that HIV-induced inflammatory pDCs impair anti-HIV stem-like memory CD8 + T cell responses and suggest that the combination of pDC depletion with PD-1 immune checkpoint blockade represents a candidate therapeutic approach to treating HIV-1 infection and its associated inflammatory diseases.
25 February 2026 in Journal of Medical Virology
The current highly active antiretroviral therapy (HAART or ART) effectively suppresses de novo HIV‐1 infection but fails to eliminate HIV reservoir cells, which leads to rapid viral rebound upon ART cessation. Chimeric antigen receptor (CAR) T cells engineered to target HIV‐1 Env⁺ cells offer a promising strategy to eliminate or control these persistent reservoirs and achieve durable control of HIV‐1 infection. However, a major challenge is the susceptibility of such CAR‐T cells to HIV infection, especially those soluble CD4 (sCD4)‐based CAR‐T cells. In this study, an sCD4‐based CAR incorporating the S85C mutation in the CD4 Ig‐like domain 1 (termed D1C) was engineered to enable disulfide bond formation with the HIV‐1 envelope glycoprotein (Env), thereby reducing viral entry and conferring protection against HIV infection. D1C/sCD4 CAR‐T cells exhibited enhanced T‐cell activation and cytotoxicity in response to Env stimulation while demonstrating resistance HIV‐1 infection in vitro and in vivo. Furthermore, the herpesvirus entry mediator (HVEM) intracellular domain was identified as an optimal costimulatory domain, enhancing cytokine induction, cytotoxicity, and promoting a favorable central memory phenotype and persistence of CAR‐T cells. In humanized mouse models, D1C/sCD4 CAR‐T cells demonstrated superior persistence and improved control of HIV rebound following ART interruption compared to wild‐type (WT)/sCD4 CAR‐T cells. These findings highlight a novel strategy to enhance the efficacy and durability of HIV‐targeted CAR‐T cell therapy by combining HIV resistance and optimized co‐stimulation.